Structural basis of species-dependent differential affinity of 6-alkoxy-5-aryl-3-pyridinecarboxamide cannabinoid-1 receptor antagonists

Molecular Pharmacology

Volumn 88, Issue 2, 2015, Pages 238-244

  Iyer, Malliga R ^a   Cinar, Resat ^a   Liu, Jie ^a   Godlewski, Grzegorz ^a   Szanda, Gergö ^a   Puhl, Henry ^a   Ikeda, Stephen R ^a   Deschamps, Jeffrey ^b   Lee, Yong Sok ^c   Steinbach, Peter J ^c   Kunos, George ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b NAVAL RESEARCH LABORATORY   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5-(4-CHLOROPHENYL)-6-(CYCLOPROPYLMETHOXY)-N-(2-HYDROXYCYCLOHEXYL)-3-PYRIDINECARBOXAMIDE; 5-(4-CHLOROPHENYL)-N-(2-HYDROXYCYCLOHEXYL)-6-(2-METHOXYETHOXY)-3-PYRIDINECARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CNR1 PROTEIN, HUMAN; CNR1 PROTEIN, MOUSE; ISOLEUCINE; NICOTINAMIDE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; RIMONABANT;

ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MOUSE; RAT; SPECIES DIFFERENCE; STRUCTURE ACTIVITY RELATION; SYNTHESIS; X RAY DIFFRACTION;

ANIMALS; BRAIN; CANNABINOID RECEPTOR ANTAGONISTS; HEK293 CELLS; HUMANS; ISOLEUCINE; MICE; MODELS, MOLECULAR; NIACINAMIDE; PIPERIDINES; PYRAZOLES; RATS; RECEPTOR, CANNABINOID, CB1; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; X-RAY DIFFRACTION;

EID: 84939795965     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.098541     Document Type: Article

References (36)

1. Abood ME, Ditto KE, Noel MA, Showalter VM, and Tao Q (1997) Isolation and expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells. Biochem Pharmacol 53:207-214.
2. Blüher M, Engeli S, Klöting N, Berndt J, Fasshauer M, Bátkai S, Pacher P, Schön MR, Jordan J, and Stumvoll M (2006) Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55: 3053-3060.
3. Collins S, Martin TL, Surwit RS, and Robidoux J (2004) Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: physiological and molecular characteristics. Physiol Behav 81:243-248.
4. Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, Johnson MR, and Martin BR (1993) Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 265: 218-226.
5. Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thöne-Reineke C, and Ortmann S et al. (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423-431.
6. Després JP, Golay A, and Sjöström L; Rimonabant in Obesity-Lipids Study Group (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134.
7. Flamment M, Gueguen N, Wetterwald C, Simard G, Malthièry Y, and Ducluzeau PH (2009) Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet. Am J Physiol Endocrinol Metab 297: E1162-E1170.
8. Griffin G, Atkinson PJ, Showalter VM, Martin BR, and Abood ME (1998) Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5′-O-(3-[35S] thio)-triphosphate binding assay in rat cerebellar membranes. J Pharmacol Exp Ther 285:553-560.
9. Govaerts SJ, Hermans E, and Lambert DM (2004) Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. Eur J Pharm Sci 23: 233-243.
10. Hanson MA, Roth CB, Jo E, Griffith MT, Scott FL, Reinhart G, Desale H, Clemons B, Cahalan SM, and Schuerer SC et al. (2012) Crystal structure of a lipid G protein-coupled receptor. Science 335:851-855.
11. Hurst DP, Lynch DL, Barnett-Norris J, Hyatt SM, Seltzman HH, Zhong M, Song ZH, Nie J, Lewis D, and Reggio PH (2002) N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol 62:1274-1287.
12. Izzo AA, Fezza F, Capasso R, Bisogno T, Pinto L, Iuvone T, Esposito G, Mascolo N, Di Marzo V, and Capasso F (2001) Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 134:563-570.
13. Jourdan T, Godlewski G, Cinar R, Bertola A, Szanda G, Liu J, Tam J, Han T, Mukhopadhyay B, and Skarulis MC et al. (2013) Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med 19:1132-1140.
14. Kapur A, Hurst DP, Fleischer D, Whitnell R, Thakur GA, Makriyannis A, Reggio PH, and Abood ME (2007) Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol Pharmacol 71:1512-1524.
15. Kim W, Doyle ME, Liu Z, Lao Q, Shin YK, Carlson OD, Kim HS, Thomas S, Napora JK, and Lee EK et al. (2011) Cannabinoids inhibit insulin receptor signaling in pancreatic β-cells. Diabetes 60:1198-1209.
16. Kraulis PJ (1991) MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl Cryst 24:946-950.
17. Kunz I, Meier MK, Bourson A, Fisseha M, and Schilling W (2008) Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats. Int J Obes (Lond) 32:863-870.
18. Le Foll B, Gorelick DA, and Goldberg SR (2009) The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) 205: 171-174.
19. Lin LS, Ha S, Ball RG, Tsou NN, Castonguay LA, Doss GA, Fong TM, Shen CP, Xiao JC, and Goulet MT et al. (2008) Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist. J Med Chem 51:2108-2114.
20. Liu YL, Connoley IP, Wilson CA, and Stock MJ (2005) Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 29:183-187.
21. McAllister SD, Rizvi G, Anavi-Goffer S, Hurst DP, Barnett-Norris J, Lynch DL, Reggio PH, and Abood ME (2003) An aromatic microdomain at the cannabinoid CB (1) receptor constitutes an agonist/inverse agonist binding region. J Med Chem 46: 5139-5152.
22. Merritt EA and Bacon DJ (1997) Raster3D: photorealistic molecular graphics. Methods Enzymol 277:505-524.
23. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Bátkai S, Harvey-White J, Mackie K, Offertáler L, and Wang L et al. (2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to dietinduced obesity. J Clin Invest 115:1298-1305.
24. Pacher P, Bátkai S, and Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389-462.
25. Perrin MA, Bauer M, Barrio M, Tamarit JL, Céolin R, and Rietveld IB (2013) Rimonabant dimorphism and its pressure-temperature phase diagram: a delicate case of overall monotropic behavior. J Pharm Sci 102:2311-2321.
26. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, and Rosenstock J; RIO-North America Study Group (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295:761-775.
27. Röver S, Andjelkovic M, Bénardeau A, Chaput E, Guba W, Hebeisen P, Mohr S, Nettekoven M, Obst U, and Richter WF et al. (2013) 6-Alkoxy-5-aryl-3-pyridinecarboxamides, a new series of bioavailable cannabinoid receptor type 1 (CB1) antagonists including peripherally selective compounds. J Med Chem 56:9874-9896.
28. Salo OM, Lahtela-Kakkonen M, Gynther J, Järvinen T, and Poso A (2004) Development of a 3D model for the human cannabinoid CB1 receptor. J Med Chem 47: 3048-3057.
29. Shim JY, Bertalovitz AC, and Kendall DA (2012) Probing the interaction of SR141716A with the CB1 receptor. J Biol Chem 287:38741-38754.
30. Shim JY, Welsh WJ, and Howlett AC (2003) Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction. Biopolymers 71:169-189.
31. Silvestri R, Cascio MG, La Regina G, Piscitelli F, Lavecchia A, Brizzi A, Pasquini S, Botta M, Novellino E, and Di Marzo V et al. (2008) Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. J Med Chem 51:1560-1576.
32. Sim-Selley LJ, Brunk LK, and Selley DE (2001) Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur J Pharmacol 414:135-143.
33. Sitkoff DF, Lee N, Ellsworth BA, Huang Q, Kang L, Baska R, Huang Y, Sun C, Pendri A, and Malley MF et al. (2011) Cannabinoid CB(1) receptor ligand binding and function examined through mutagenesis studies of F200 and S383. Eur J Pharmacol 651:9-17.
34. Tam J, Cinar R, Liu J, Godlewski G, Wesley D, Jourdan T, Szanda G, Mukhopadhyay B, Chedester L, and Liow JS et al. (2012) Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab 16:167-179.
35. Tam J, Vemuri VK, Liu J, Bátkai S, Mukhopadhyay B, Godlewski G, Osei-Hyiaman D, Ohnuma S, Ambudkar SV, and Pickel J et al. (2010) Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 120:2953-2966.
36. Thomas BF, Francisco ME, Seltzman HH, Thomas JB, Fix SE, Schulz AK, Gilliam AF, Pertwee RG, and Stevenson LA (2005) Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities. Bioorg Med Chem 13:5463-5474.